News

Reuters8mon
Regeneron loses key defense in COVID-19 treatment patent lawsuit
Oct 4 - Biotech company Regeneron Pharmaceuticals (REGN.O ... that it misused a patented protein while testing a COVID-19 treatment. U.S. District Judge Philip Halpern rejected Regeneron's ...
Stocktwits on MSN8d
Regeneron Stock Drops On Mixed Results For Smoker’s Lung Treatment
Regeneron Pharmaceuticals (REGN) shares dropped nearly 10% in premarket trading Friday after mixed results from late-stage ...
Clinical Trials Arena on MSN5d
Sanofi and Regeneron report results from two Phase III trials of COPD treatment
Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in ...
Fierce Biotech8d
Sanofi, Regeneron's IL-33 drug fails one of 2 COPD studies as FDA timeline thrown in doubt
Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not ...
Itepekimab Failure A Setback For Sanofi And Regeneron
Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...
Pharmabiz7d
Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies
Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...